Sarepta to price new Duchenne gene therapy at $3.2M

The Cambridge drugmaker's newly approved gene therapy for Duchenne muscular dystrophy is a one-time treatment.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 22, 2023 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news